Retina Institute Japan K.K., which employes Nobel Prize-winning stem-cell technology to treat eye diseases, plans to sell a stake in itself to a group of Japanese companies next month, ahead of a possible initial public offering in five years.
The company will raise ¥1 billion from the sale to fund development of a treatment for age-related macular degeneration — a leading cause of blindness in the elderly — using technology developed by the Riken research institute, Retina Chief Executive Officer Hardy Kagimoto said.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.